HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

FEED

ENvue Medical, Inc. (NASDAQ)

Healthcare — Medical Devices

ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at-home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. The company was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Tyler, Texas.

None
$0.57
+$0.06 (+10.68%)
Sign in to add FEED to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$3.47M
P/E Ratio (TTM)-
Forward P/E-
EPS (TTM)$-3.67
Dividend Yield-
Profit Margin-
Revenue Growth-36.30%
ROE-59.49%
Debt/Equity3.78
Recommendation None
Analyst Target-
Analysts-
Indexes NASDAQ

Technical Indicators

RSI (14)22.6
Beta1.50
SMA 20-
SMA 40-
52-Week High$17.40
52-Week Low$0.51
50-Day Avg$0.96
200-Day Avg$2.94
Avg Volume890.8K
Volume276.4K

Performance Analysis

NEUTRAL

FEED presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($0.51), which could present a value opportunity.
+ RSI at 22.6 signals oversold conditions — a bounce may be ahead.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
- Revenue declined 36.3% year-over-year.
~ Wall Street consensus is "none".

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:09 UTC

Back to Screener Export Report